Prof Ananya💙 @achoud72.bsky.social

NHS consultant no private work. Equality, liberty and justice, Chair in Clinical Oncology, Christie & University of Manchester, EIC BMJ Oncology. Own views

[Mirrors of Medicine @mirrorsmed]

🎥 @achoud72 invites you to the Global Forum on GU Oncology!

🌟 Join a global faculty for case-based, multidisciplinary discussions in bladder, renal, and prostate cancer
🌟 Translating the latest GU oncology data to practical takeaways for your clinical practice

📅 2-5 December 2026 | 📍 Amsterdam

👉 Register now: https://t.co/LbvgMIQ9XB

@OncoAlert #RENALC26 #BLADDR26 #PROSCA26

[Daniel E Spratt @DrSpratticus]

#ASCO26
Talk about real-time updates. NEJM paper now online and my predictions and inferences appear true.

Majority of MFS events were by PET not conventional imaging. "Most distant metastases were identified by PSMA PET (53.0% of those in the apalutamide group and 60.7% in the placebo group)"

VERY IMPORTANTLY: "No significant between-group difference was observed in metastasis-free survival assessed with conventional imaging alone (hazard ratio, 0.84; 95% CI, 0.67 to 1.07)"

Not only does MFS cross 1, but the HR also crosses the surrogate threshold effect (0.81).

@urotoday @PCF_select @US_FDA

[Daniel E Spratt @DrSpratticus]

#ASCO26
The PROTEUS trial results are now online...buckle up as we wait to see the full presentation. This is going to be a trial that is likely highly controversial until the full results are published.

Some may call this a homerun, others may call this the largest negative trial @ASCO 2026. Up to you to interpret!

@urotoday @EricTopol @DrChoueiri @neerajaiims @ASCO @US_FDA @NCCN @myESMO @ASTRO_org @PCF_Science @declangmurphy @mcuban

[Prof Ananya💙 @achoud72.bsky.social @achoud72]

@oncology_bg Congratulations @oncology_bg Ready for the next chapter!🎉

[NonsparseOncologist @5_utr]

Liang et al. (2019) screened 3,262 trials, found 57 Phase II -> III pairs, then were SHOCKED that the selected promising Phase IIs had bigger effects than Phase III. Let’s pull it apart for teaching sake 🧵 1/n

[David Woolf @ClinOncologist]

Team Manchester/ Christie bids farewell to ESTRO26!

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
UK National Breast Radiotherapy Audit: Real-World Heart and Lung Doses from 30,000 NHS Treatment Plans Presented by Imogen Locke 🇬🇧
#RadOnc ☢️ #BreastCancer

UK National Breast Radiotherapy Audit: Real-World Heart and Lung Doses from 30,000 National Health Service Radiotherapy Treatment Plans has been published. NHS England Supported a nationally co-ordinated quality improvement programme using ProKnow. 48 out of 49 centres in England contributed to the Audit and it demonstrates the feasibility of high-quality large scale real world dosimetric data collection and evaluation across the NHS. Heart and lung doses are low and comparable to international benchmarks. Dosimetric variation exists between centres, particularly in VMAT planning, identifying opportunities for improvement and further audits are underway

@CUH_NHS
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Low-level laser therapy for radiation-induced oral mucositis: a prospective clinical trial (IRCT20191107045357N2) Presented by Ahmad Ameri 🇮🇷 @AhmadAmeri9
#RadOnc ☢️

Low-level laser therapy (LLLT) was evaluated in a prospective double-blind trial for radiation-induced oral mucositis in head and neck cancer. In 53 patients with paired lesions, LLLT significantly reduced pain and severity from week one and week three versus sham treatment, respectively. Healing rates were higher (52.4% vs 11.9%). No adverse effects occurred. LLLT appears to be an effective supportive care option for reducing mucositis burden.

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Acute Toxicity in the DESTINATION 1 Trial: A Prospective Prostate SBRT Dose De-escalation Feasibility Study Presented by Sian Cooper 🇬🇧

DESTINATION 1 is a prospective Phase II/R-IDEAL 2B federated trial evaluating MR-guided focal boost SBRT (45 Gy/5# to dominant lesion; 30 Gy/5# whole prostate with no margin) in 60 patients with localised prostate cancer across three international centres. At 12 weeks, no grade ≥3 toxicity was observed. GU grade ≥2 toxicity was 55%, GI grade ≥2 was 11.7%. The novel federated design demonstrates proof-of-concept for efficient, standardised international adaptive radiotherapy trials.

#RadOnc ☢️
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
PERSIAN TRIAL (NCT03449719): a randomized phase II trial testing Apalutamide and SBRT for hormone-sensitive prostate cancer Presented by Giulio Francolini 🇮🇹
#RadOnc ☢️

The PERSIAN randomized phase II trial evaluated apalutamide ± SBRT in oligometastatic hormone-sensitive prostate cancer. Biochemical response rates were high in both arms, with no significant differences overall. A consistent numerical trend favoring SBRT was observed, particularly in patients with higher disease burden. Treatment was well tolerated, with limited interruptions. These findings suggest a potential role for SBRT alongside systemic therapy in selected patients.

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Prospective randomized controlled trial of hyaluronic acid spacer for hypofractionated prostate radiation therapy: 3-year results
Presented by Martin King 🇺🇸 @MtkingMD
#RadOnc ☢️ #ProstateCancer

In a prior report of a modern multi-institutional randomized trial with prospective plan review, the stabilized hyaluronic acid (sHA) rectal spacer reduced acute grade 2 or higher gastrointestinal (GI) adverse events after hypofractionated radiation therapy. In this more recent analysis, the sHA spacer reduced late (6-36 month) grade 2 or higher GI adverse events (3-year cumulative incidences of 9.5% for spacer versus 0% for no spacer).

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[Paul Sargos @PaulSargos]

👌 Just back from #ESTRO26 .

🙏 Honored to give several presentations and chair multiple sessions during a congress marked by outstanding science, strong educational value, and inspiring discussions with good friends from around the world.

👍 See you in Milan #ESTRO27

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Results of a Randomized Non-Inferiority Trial of Hypofractionation via Extended versus Accelerated Therapy (HEAT) for Prostate Cancer Presented by Matthew C. Abramowitz🇺🇸
#RadOnc ☢️ #ProstateCancer

HEAT is an international phase III randomized non-inferiority study comparing 5-fraction accelerated-hypofractionated radiotherapy (AHRT) with 26-fraction extended-hypofractionated radiotherapy (EHRT) for localized low/intermediate-risk prostate cancer ± ADT. At median follow-up of 59.7 months, AHRT demonstrated non-inferior biochemical failure. Acute grade ≥2 gastrointestinal toxicity was lower with AHRT, with no significant differences in late gastrointestinal or acute/late genitourinary toxicity. This supports AHRT as an effective, well-tolerated treatment for localized prostate cancer.

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Great Day 4 of #ESTRO26 in Stockholm
Introducing Dr. Alexander Cherry 🇺🇸with abstract nbr 846 Optimising oligometastatic disease management with circulating tumor DNA 🧬

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

A GREAT DAY FOUR of #ESTRO26 in Stockholm!!

Our Thanks our Congratulations to our dear friends at ESTRO for an amazing Meeting!!
Thanking our Colleagues for supporting YOUR OncoAlert🚨Network
✅️ 21 Million impressions Worldwide on X
✅️1.4k Posts and the numbers are still coming
WE ARE OncoAlert, By Colleagues For Colleagues

@_ShankarSiva
@to_be_elizabeth
@PBlanchardMD
@piet_ost
@ESTRO_RT
@AmadeoWals
@5_utr
@DavidSherMD
@jryckman3
@DrSpratticus
@Icro_Meattini
@DrewMoghanaki
@radoncreview
@UTMDAnderson
@DrHBurstein
@brachyexpert
@drdavidpalma
@jaydetsky
@DrLesterColl
@LuisAlberto3P
@achoud72

#RadOnc
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@MKnoll_MD
@seanmmcbride
@NiuSanford

[OncoAlert @OncoAlert]

Great Day 5 of #ESTRO26 🚨
A Great Pleasure to present Dr. Shankar Siva🇦🇺 with Abstract nbr 505

Final Results of the TROG 15.01 FASTRACKII Clinical Trial: Stereotactic Ablative Body Radiotherapy (SABR) for Primary #KidneyCancer

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Great Day 5 of #ESTRO26 🚨
A Great Pleasure to present Dr. David Krug🇩🇪 with abstract 5611: Metastases directed treatment in patients with oligometastatic #BreastCancer : Results from the OLIGOMA trial

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Great Day 4 of #ESTRO26
A Great Pleasure to present this great interview with Professor. Thomas Bortfeld 🇺🇸

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Personalising Radiotherapy Dose in Anal Cancer (PLATO) Platform: 6-month patient reported outcomes across ACT3, ACT4 and ACT5 trials
Presenter Alexandra Gilbert 🇬🇧

The PLATO platform evaluates risk adapted radiotherapy dosing for anal squamous cell carcinoma across the disease spectrum. We report patient reported outcomes (PROs) using the EORTC-QLQ-C30 and QLQ ANL27 after 6-months follow-up. 706 patients were analysed (ACT3/4/5) with excellent PRO compliance. All treated groups experienced marked end of treatment declines with recovery by 6-months for most issues. ACT5 patients reported worse baseline PROs and persistently poorer bowel function at 6-months. Longer follow up will characterise late-effects.

#RadOnc
@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth

[OncoAlert @OncoAlert]

Day FOUR of #ESTRO26 Coverage by OncoAlert 🚨
Five-year Results of the OPERA Trial: When and How to Assess Tumor Response to Guide Rectal Preservation Presented by Syrine Ben Dhia 🇫🇷
#RadOnc ☢️

This post-hoc analysis of the OPERA trial evaluated early tumor response assessment (week 14) in rectal adenocarcinoma using clinical examination, including digital rectal examination and rigid rectoscopy. At week 14, 76% of patients showed a good response, strongly correlating with MRI findings. Most were managed with watch-and-wait, achieving similar 5-year organ preservation rates to later assessments. Outcomes were comparable between complete and near-complete responses, indicating early assessment is reliable and that near-complete response should not prompt radical surgery decisions.

@ESTRO_RT
@yasemin09896924
@LindaMrissa
@christian_roenn
@Valeriadionisi
@gerryhanna
@clchiang_hk
@mtugceyilmaz
@B_Tomasik
@gmpetrianni
@CiroFranzese1
@Atem84
@piet_ost
@brachyexpert
@BlanceS90
@The_PT_Explorer
@BarbaraJereczek
@Mat_Guc
@ZilliThomas
@AnnaKirby17
@PBlanchardMD
@achoud72

Pinging OA faculty
@MKnoll_MD
@_ShankarSiva
@Icro_Meattini
@seanmmcbride
@NiuSanford
@nataliagandur
@acampsmalea
@to_be_elizabeth